Insurance status and the risk of severe respiratory syncytial virus disease in United States preterm infants born at 32–35 weeks gestational age
JA Franklin, EJ Anderson, X Wu…�- Open forum�…, 2016 - academic.oup.com
Background. Database studies have identified that public health insurance status is
associated with an increased risk of severe respiratory syncytial virus (RSV) disease in US�…
associated with an increased risk of severe respiratory syncytial virus (RSV) disease in US�…
[HTML][HTML] Impact of the 2014 American Academy of Pediatrics immunoprophylaxis policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations�…
LR Krilov, J Fergie, M Goldstein…�- American journal of�…, 2020 - thieme-connect.com
Objective This study examined the rate, severity, and cost of respiratory syncytial virus (RSV)
hospitalizations among preterm infants 29 to 34 weeks gestational age (wGA) versus term�…
hospitalizations among preterm infants 29 to 34 weeks gestational age (wGA) versus term�…
[HTML][HTML] Respiratory syncytial virus disease in preterm infants in the US born at 32–35 weeks gestation not receiving immunoprophylaxis
CS Ambrose, EJ Anderson, EAF Sim�es…�- The Pediatric�…, 2014 - journals.lww.com
Background: The Respiratory Syncytial Virus (RSV) Respiratory Events Among Preterm
Infants Outcomes and Risk Tracking (REPORT) study evaluated RSV disease burden in US�…
Infants Outcomes and Risk Tracking (REPORT) study evaluated RSV disease burden in US�…
[HTML][HTML] Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of�…
LR Krilov, EJ Anderson�- Journal of Perinatology, 2020 - nature.com
Palivizumab is the only licensed and effective immunoprophylaxis (IP) available to prevent
respiratory syncytial virus (RSV) infection in high-risk infants including infants born at≤ 35�…
respiratory syncytial virus (RSV) infection in high-risk infants including infants born at≤ 35�…
Long-term assessment of healthcare utilization 5 years after respiratory syncytial virus infection in US infants
EAF Sim�es, V Chirikov, M Botteman…�- The Journal of�…, 2020 - academic.oup.com
Background Respiratory syncytial virus (RSV) is the primary cause of respiratory tract
infections in infants; however, current burden estimates report only the short-term effects of�…
infections in infants; however, current burden estimates report only the short-term effects of�…
[HTML][HTML] Increasing rates of RSV hospitalization among preterm infants: a decade of data
AM Kong, IH Winer, NM Zimmerman…�- American Journal of�…, 2023 - thieme-connect.com
Objective In 2014, the American Academy of Pediatrics (AAP) changed its policy on the use
of respiratory syncytial virus immunoprophylaxis (RSV-IP) so that RSV-IP was no longer�…
of respiratory syncytial virus immunoprophylaxis (RSV-IP) so that RSV-IP was no longer�…
[HTML][HTML] Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or�…
J Figueras-Aloy, P Manzoni, B Paes…�- Infectious diseases and�…, 2016 - Springer
Abstract Introduction The REGAL (RSV Evidence—a Geographical Archive of the Literature)
series provide a comprehensive review of the published evidence in the field of respiratory�…
series provide a comprehensive review of the published evidence in the field of respiratory�…
Healthy Late-preterm infants born 33–36+ 6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization
AM Helfrich, CM Nylund, MD Eberly, MB Eide…�- Early human�…, 2015 - Elsevier
Background Respiratory syncytial virus (RSV) is a leading cause of hospitalization for
children< 1 year old and is more severe in premature infants. Objective To assess whether�…
children< 1 year old and is more severe in premature infants. Objective To assess whether�…
[HTML][HTML] Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States
RC Parikh, KK McLaurin, AV Margulis…�- Infectious Diseases and�…, 2017 - Springer
Introduction Respiratory syncytial virus (RSV) is the leading cause of hospitalization among
infants in the United States, and the risk for RSV hospitalizations is greater for infants born�…
infants in the United States, and the risk for RSV hospitalizations is greater for infants born�…
[HTML][HTML] Impact of the 2014 American Academy of Pediatrics policy on RSV hospitalization in preterm infants in the United States
M Goldstein, J Fergie, LR Krilov�- Infectious Diseases and Therapy, 2021 - Springer
Despite being a leading cause of hospitalization due to lower respiratory tract infections, the
treatment of respiratory syncytial virus (RSV) infection is primarily supportive. Palivizumab is�…
treatment of respiratory syncytial virus (RSV) infection is primarily supportive. Palivizumab is�…
Related searches
- preterm infants insurance status
- preterm infants gestational age
- gestational age insurance status
- preterm infants rsv hospitalization
- preterm infants american academy
- preterm infants virus infection
- preterm infants associated morbidity
- preterm infants increasing rates
- preterm infants lung disease
- preterm infants pediatrics policy
- preterm infants full term
- gestational age higher risk
- rsv hospitalization increasing rates
- rsv hospitalization pediatrics policy
- rsv hospitalization american academy
- virus infection lung disease